Abstract Number: 503 • 2014 ACR/ARHP Annual Meeting
Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial
Background/Purpose There is good evidence that folic acid 5-10mg per week leads to reduction in methotrexate (MTX) toxicity in rheumatoid arthritis (RA). However, this data…Abstract Number: 502 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab
Background/Purpose : Tocilizumab, as an intra-venous agent, has been approved for rheumatoid arthritis (RA) in Canada in April 30th, 2010. It was the sixth approved…Abstract Number: 501 • 2014 ACR/ARHP Annual Meeting
Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…Abstract Number: 500 • 2014 ACR/ARHP Annual Meeting
Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement
Background/Purpose Dose reduction and discontinuation of TNF inhibitors (TNFi) is feasible in many rheumatoid arthritis (RA) patients, but leads to (temporary) worsening of disease activity…Abstract Number: 499 • 2014 ACR/ARHP Annual Meeting
Biologic Discontinuation in Rheumatoid Arthritis: Experience from a Canadian Clinic
Background/Purpose: Adherence and persistence to treatment are a cornerstone of treatment success in chronic diseases such as rheumatoid arthritis (RA). The purpose of this study…Abstract Number: 518 • 2014 ACR/ARHP Annual Meeting
Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry
Background/Purpose: Rituximab is a chimeric monoclonal antibody for the treatment of rheumatoid arthritis (RA). Prolonged B-cell depletion from repeated doses of rituximab may be associated…Abstract Number: 517 • 2014 ACR/ARHP Annual Meeting
Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results
Background/Purpose Tocilizumab (TCZ) has been approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or as combination with disease-modifying antirheumatic drugs…Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting
The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…Abstract Number: 506 • 2014 ACR/ARHP Annual Meeting
Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis
Background/Purpose: For active rheumatoid arthritis (RA) patients with inadequate response to synthetic DMARDs, biologic agents, such as TNF inhibitor and IL-6 receptor inhibitor, are indicated.…Abstract Number: 507 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab Therapy in Japanese Patients with Rheumatoid Arthritis
HIGH RATE OF IMPROVEMENT IN SERUM MATRIX METALLOPROTEINASE-3 LEVELS AT 4 WEEKS PREDICT REMISSION AT 52 WEEKS IN RA PATIENTS WITH ADALIMUMAB THERAPY Background/Purpose : Serum…Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting
Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…Abstract Number: 509 • 2014 ACR/ARHP Annual Meeting
Etanercept Have Better Drug Survival Than Monoclonal Antibodies in Rheumatoid Arthritis: Results of Single Center Hur-BIO Registry
Etanercept have better drug survival than monoclonal antibodies in Rheumatoid Arthritis: Results of single center HÜR-BÝO registryBackground/Purpose: In routine practice, observational registries may show retention…Abstract Number: 510 • 2014 ACR/ARHP Annual Meeting
Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept – Results from the National Swedish Rheumatology Quality Register
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting
First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…Abstract Number: 512 • 2014 ACR/ARHP Annual Meeting
Effect and Safety of Concomitant Methotrexate and Tacrolimus on Clinical Response of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Biological Dmards
Background/Purpose Abatacept (ABT) is a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to…
ACR Meeting Abstracts